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Novelty and Impact: India has the largest burden of cervical cancer in the world. To quantify the 
consequences of delaying implementation of organized cervical cancer screening in India, we used 
mathematical models to estimate the cumulative number of cervical cancer cases and deaths averted 
under different program implementation scenarios. Delays in implementation of screening programs in 
high-burden settings will result in substantial morbidity and mortality among women beyond the age for 
adolescent HPV vaccination. 
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ABSTRACT 
India has the highest burden of cervical cancer in the world. To estimate the consequences of delaying 
implementation of organized cervical cancer screening, we projected the avertable burden of disease 
under different implementation scenarios of a screening program. We used an individual-based 
microsimulation model of human papillomavirus (HPV) infection and cervical cancer calibrated to 
epidemiologic data from India to project age-specific cancer incidence and mortality reductions 
associated with screening (once-in-a-lifetime among women aged 30 to 34 years) with one-visit visual 
inspection with acetic acid (VIA) and one- and two-visit HPV DNA testing. We then applied these 
reductions to a population model to project the lifetime cervical cancer cases and deaths averted under 
different implementation scenarios taking place from 2017 to 2026: 1) immediate implementation of 
screening with currently available screening tests (one-visit VIA, two-visit HPV testing); 2) immediate 
implementation of screening with currently available screening tests, with a switch to point-of-care one-
visit HPV testing in five years; and 3) five-year delayed implementation of screening with current 
screening tests or point-of-care HPV testing. Immediate implementation of two-visit HPV testing with a 
switch to one-visit HPV testing averted 574,100 cases and 382,500 deaths over the lifetimes of 81.4 
million 30 to 34-year-old women screened once between 2017 and 2026. Delayed implementation with 
a one-visit HPV test averted 209,300 cases and 139,100 deaths. Delays in implementation of screening 
programs in high-burden settings will result in substantial morbidity and mortality among women 
beyond the age for adolescent HPV vaccination.  
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Background  
India has the largest burden of cervical cancer in the world, with an estimated 123 000 incident 
cases occurring annually.1 This accounts for approximately 23% of cases worldwide, and 32% of cases in 
less developed countries.1 Yet the disease is preventable through either prophylactic vaccination against 
human papillomavirus (HPV)Ͷ the sexually transmitted virus that causes cervical cancerͶ or screening 
and treatment of precancerous lesions caused by persistent HPV infection. While the introduction and 
scale-up of adolescent HPV vaccination programs would substantially reduce the number of cervical 
cancer cases in years to come, the full benefits of HPV vaccination will not be realized for more than 30 
years; to date, there are several HPV vaccination demonstration projects in India, but the vaccine is not 
available through the national immunization program.2 In the interim, screening is the only form of 
prevention for the two to three generations of women beyond the target age of adolescent vaccination. 
Only an estimated 3.1% of women in India reported receiving a Pap smear in the last 3 years.3 
The World Health Organization (WHO) recommends screening with HPV DNA testing where 
resources are available; visual inspection with acetic acid (VIA) represents an acceptable alternative in 
low-resource settings.4 Recent guidelines from the American Society for Clinical Oncology recommend 
HPV testing for all resource levels, and if resources are not available, VIA should be offered with the goal 
of developing screening infrastructure and switching to HPV testing as soon as possible.5 Promising 
developments to improve the delivery of preventive care in low-resource settings include the 
introduction of low-cost HPV tests with samples collected by either a health provider or the woman 
herself;6 advances in the use of mobile phones for reaching patients;7 and introduction of preventive 
treatment technologies that do not rely on compressed gas, which may be difficult and costly to obtain.8 
Additionally, new clinically validated technology exists to facilitate point-of-care (i.e., one-visit screen-
and-treat) HPV testing, but has not yet been implemented outside of small demonstration projects.9 But 
like other lower-middle income settings, India faces shortages of health workers, insufficient referral 
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processes, and financial constraints that have impeded the success of organized screening that 
systematically targets eligible women. While operational guidelines developed by the Ministry of Health 
recommend screening with VIA every 5 years for women over age 30 years, with initial implementation 
in 100 districts providing data, states will need to fund and implement broader efforts.10, 11 Without 
substantial political will and the injection of government and donor funds, the implementation of 
screening programs will likely continue to stall. 
To provide information on the consequences of further delays in the implementation of cervical 
cancer screening, we quantified the potential health impact of an organized national screening program 
in India by estimating the cumulative number of cervical cancer cases and deaths averted over the 
lifetimes of women aged 30 to 34 years under different implementation scenarios taking place from 
2017 to 2026: 1) immediate implementation of screening with currently available screening tests (i.e., 
VIA, HPV DNA testing); 2) immediate implementation of screening with currently available screening 
tests, with a switch to point-of-care HPV testing in five years; and 3) five-year delayed implementation 
of screening with current screening tests or point-of-care HPV testing. 
 
METHODS 
Study design and data sources 
We used an individual-based microsimulation model of the natural history of HPV infection and 
cervical cancer12Ͷ calibrated to epidemiologic data on cervical disease burden in India13Ͷ to estimate 
the reductions in cervical cancer incidence and mortality attributable to screening with either VIA or 
HPV DNA testing. Assumptions and data inputs pertaining to the effectiveness of each test, including 
coverage of the target population, test performance, compliance with recommended follow-up, 
eligibility for cryotherapy, and treatment efficacy, are presented in Table 1.1, 6, 13-19  We then applied the 
percent reductions in cervical cancer incidence and mortality in each five-year age group from ages 30 
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to 79 years to population and disease burden data using the Excel-based CERVIVAC model, a tool 
ĚĞǀĞůŽƉĞĚĨŽƌƚŚĞWĂŶŵĞƌŝĐĂŶ,ĞĂůƚŚKƌŐĂŶŝǌĂƚŝŽŶ͛Ɛ(PAHO) ProVac Initiative that contains separate 
modules for evaluating the costs and health impact associated with either HPV vaccination or cervical 
cancer screening and treatment of precancerous lesions. Female population data by birth cohort were 
based on estimates for India through 2100 from the United Nations Population Division (the 2012 
revision).17 Cervical cancer incidence and mortality rates in the absence of screening were based on 
GLOBOCAN 2012, produced by the International Agency for Research on Cancer (IARC).1 The CERVIVAC 
model was used to estimate the numbers of cervical cancer cases and deaths averted for each 
implementation scenario based on screening test, age at screening, screening coverage of the target 
population, and year of implementation.   
 
Statistical analysis 
The individual-based microsimulation model of the natural history of HPV infection and cervical 
cancer, as well as the model calibration process, have been previously described.12, 13 In brief, the model 
tracks individual girls who enter the model at age 9 years with a healthy cervix and then transition 
between mutually exclusive health states that include HPV infection, cervical intraepithelial neoplasia 
(CIN) (grade 2 or 3), and invasive cervical cancer. As individuals age, they can acquire HPV infections, 
which may either clear or progress to CIN2 or CIN3. Women with CIN2 or CIN3 may regress or progress 
to invasive cancer, which can be detected at the local, regional, or distant stage. Transition probabilities 
may vary by age, HPV type (stratified by HPV 16, 18, 31, 33, 45, 52, 58, other high-risk types, and low-
risk types), duration of infection or CIN status, and naturally acquired immunity from prior HPV 
infection. Death from non-ĐĞƌǀŝĐĂůĐĂƵƐĞƐĐĂŶŽĐĐƵƌŝŶĂŶǇŚĞĂůƚŚƐƚĂƚĞ͕ĚĞƉĞŶĚŝŶŐŽŶĂǁŽŵĂŶ͛ƐĂŐĞ͕
and stage-specific excess mortality due to cervical cancer can occur after its onset.  
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To calibrate the model to epidemiologic data on age-specific high-risk HPV prevalence6 and 
cervical cancer incidence from India,18 ǁĞĞƐƚŝŵĂƚĞĚďĂƐĞůŝŶĞ͞ƉƌŝŽƌ͟ŝŶƉƵƚƉĂƌĂŵĞƚĞƌǀĂůƵĞƐfor natural 
history transitions using longitudinal data.20-23 To reflect heterogeneity in age- and type-specific HPV 
incidence between India and input source study locations, as well as uncertainty surrounding natural 
immunity following initial infection and progression and regression of CIN2 and CIN3, we set plausible 
ranges around these input parameter values. Repeated model simulations (in the absence of any 
intervention) selected a single random value from the plausible range for each uncertain parameter, 
creating a unique natural history input parameter set. For each unique parameter set, we computed a 
goodness-of-fit score by summing the log-likelihood of model-projected outcomes to represent the 
quality of fit to epidemiologic data from India (i.e., calibration targets). We selected the top 50 good-
fitting input parameter sets to use in analyses as a form of probabilistic sensitivity analysis. Natural 
history model inputs for the India microsimulation model, as well as model fit to epidemiologic data, are 
presented in the Appendix. 
We used the calibrated microsimulation model to estimate the average percent reduction in 
cervical cancer incidence and mortality in each five-year age group (from ages 30 to 79 years; reductions 
in women aged 80 to 100 years were assumed to be the same as in women aged 75 to 79 years) 
associated with the following screening tests, administered once in a lifetime, relative to no 
intervention: 1) one-visit VIA; 2) two-visit HPV DNA testing; and 3) one-visit point-of-care HPV DNA 
testing (Table 2) at screening coverage levels of 10% and 20% of women aged 30 to 34 years. For VIA, 
we assumed that women who were screen-positive and eligible for cryotherapy were treated at the 
same clinical visit. For two-visit HPV DNA testing, we assumed women self-collected a vaginal HPV 
specimen during an initial clinical encounter, and subsequently received results and treatment (if HPV-
positive and eligible for cryotherapy) in a separate visit. For one-visit HPV DNA testing, we assumed that 
self-collection and treatment of HPV-positive eligible women took place in a single visit. In all strategies, 
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women who were not eligible for cryotherapy were referred to further diagnostic testing with 
colposcopy, and subsequent treatment if they received a histologic diagnosis of CIN1 or higher. Loss to 
follow-up rates were assumed to be 20% per clinical encounter. 
The CERVIVAC model was then used to estimate the number of cervical cancer cases and deaths 
averted over the lifetimes of women aged 30 to 34 years for the following implementation scenarios 
between 2017 and 2026, relative to no screening: 1) immediate implementation of screening with one-
visit VIA beginning in 2017 (͞/ŵŵĞĚŝĂƚĞs/͟); 2) immediate implementation of screening with two-visit 
HPV DNA testing beginning in 2017 (͞/ŵŵĞĚŝĂƚĞtwo-visit ,Ws͟); 3) immediate implementation of 
screening with VIA beginning in 2017 and switching to point-of-care HPV testing (i.e., one-visit HPV 
ƚĞƐƚŝŶŐͿŝŶϮϬϮϮ;͞/ŵŵĞĚŝĂƚĞs/͕ƐǁŝƚĐŚƚŽone-visit ,Ws͟Ϳ͖ϰͿŝŵŵĞĚŝĂƚĞŝŵƉůĞŵĞŶƚĂƚŝŽŶŽĨƐĐƌĞĞŶŝŶŐ
with two-visit HPV DNA testing beginning in 2017 and switching to one-visit HPV testing in 2022 
;͞/ŵŵĞĚŝĂƚĞtwo-visit HPV, switch to one-visit ,Ws͟Ϳ͖ϱͿdelayed implementation of screening with one-
visit VIA, beginning in 2022 (͞ĞůĂǇĞĚs/͟); 6) delayed implementation of screening with two-visit HPV 
DNA testing, beginning in 2022 (͞ĞůĂǇĞĚtwo-visit ,Ws͟); 7) delayed implementation of screening with 
one-visit point-of-care HPV testing in 2022 (͞ĞůĂǇĞĚone-visit ,Ws͟). Screening modalities were 
ƐĞůĞĐƚĞĚďĂƐĞĚŽŶ/ŶĚŝĂ͛ƐŽƉĞƌĂƚŝŽŶĂůŐƵŝĚĞůŝŶĞƐ͕ǁŚŝĐŚƌĞĐŽŵŵĞŶĚs/͕11 and HPV DNA testing, which 
has been demonstrated as cost-effective in previous modeling work.13 For strategies involving 
immediate implementation, we assumed initial coverage was 10% each year of each birth cohort of 
women aged 30 to 34 years in that year for the first five years of the screening program (2017-2021), 
and then increased to 20% each year of each birth cohort aged 30 to 34 years in the next 5 years of the 
program (2022-2026). For strategies involving delayed implementation, we assumed no screening from 
2017-2021 and 10% coverage each year of each birth cohort of women aged 30 to 34 years from 2022-
2026.  Thus, depending on the year, cohort, and coverage level, effective coverage for a particular birth 
cohort considered could be zero (e.g., for 34 year old women in 2017 under delayed implementation 
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scenarios), or nearly 100% (e.g., for 30 year old women in 2022 after immediate implementation with a 
switch to 1-visit HPV). 
 
 
RESULTS 
Without screening, the CERVIVAC model projected 3,824,700 cervical cancer cases and 
2,878,300 deaths over the lifetimes of women aged 30 to 34 years between 2017 and 2026 (equivalent 
to lifetime risks of 2.5% and 1.9%, respectively, of the 151 million women alive in these cohorts when 
each first became eligible for screening). The cumulative number of cervical cancer cases and deaths 
that could potentially be averted over the lifetimes of women in India aged 30 to 34 years during the 
intervention period (2017-2026) are presented in Table 3; the timing of cases and deaths averted, by 
calendar year, is displayed in Figure 1. Scenarios involving immediate implementation of screening in 
2017 were predicted to avert substantially more cervical cancer cases and deaths than scenarios that 
delayed implementation until 2022. Immediate implementation of two-visit HPV testing with a switch to 
one-visit HPV testing was the most effective scenario, averting an estimated 574,100 cases and 382,500 
deaths. Immediate implementation of VIA with a switch to one-visit HPV testing was the next most 
effective scenario, and was projected to avert 521,900 cases and 346,600 deaths.  
Among immediate implementation strategies involving only currently available screening tests, 
immediate two-visit HPV testing was more effective than immediate VIA, averting an estimated 
additional 149,800 cases and 110,100 deaths. 
Despite comparable single-visit delivery and more favorable test sensitivity to detect CIN2 and 
higher, delayed implementation of one-visit HPV testing averted fewer cases and deaths than 
immediate implementation of VIA. Delayed implementation of one-visit HPV testing averted 364,800 
fewer cases and 243,400 fewer deaths than immediate two-visit HPV with a switch to one-visit HPV. 
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Delayed implementation of two-visit HPV testing and one-visit VIA were projected to avert the fewest 
number of cases and deaths. 
 
DISCUSSION 
This study supports the position that even short delays implementing organized screening 
programs in low-resource settings with a high cervical cancer burden will result in substantial morbidity 
and loss of life. We used a model-based approachͶ relying on both an individual-based microsimulation 
model that captures the reduction in disease burden associated with nuanced screening algorithms and 
a population modelͶ to project the number of cervical cancer cases and deaths that could be averted 
with immediate implementation of organized cervical cancer screening in India versus a five-year delay 
in implementation. Our roll-out assumptions were conservative, assuming only 10% of each birth cohort 
of women aged 30 to 34 years received screening in each of the first five years of implementation. For 
immediately implemented strategies, we assumed scale-up to 20% coverage after five years (either 
continuing with currently available screening testsͶ VIA or two-visit HPVͶ or introducing a new one-
visit HPV test). Among the strategies considered for delayed implementation was one-visit HPV testing, 
to determine whether waiting for technological improvements (i.e., point-of-care HPV testing) can 
overcome the potential loss of life due to postponing roll-out. Even under assumptions of low 
population coverage over the next ten years, we projected that immediate implementation of two-visit 
HPV testing with a switch to one-visit HPV testing can avert 574,100 cases and 382,500 deaths in India. If 
implementation is delayed by five years to wait for an improved HPV test that facilitates same-day 
screening and treatment of precancer, 364,800 fewer cases and 243,400 fewer deaths will be averted. 
Our model projections also indicate that even if a point-of-care test does not become widely available in 
five years, immediate implementation of two-visit HPV testing with moderate scale-up may still avert 
480,600 cases and 328,000 deaths relative to no screening. 
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Three large randomized trials have demonstrated that screening can reduce cervical cancer 
incidence and mortality in India. In the Osmanabad district, a single round of HPV testing reduced 
advanced cervical cancer incidence and mortality by approximately 50%,24 while VIA did not. However, a 
single round of VIA in Dindigul district reduced incidence and mortality by 25% and 35%, respectively.25 
Multiple rounds of VIA in Mumbai reduced cancer mortality by approximately 30%,26 but this was likely 
due to earlier detection of cancer rather than reduced incidence, and required extensive training of 
health workers. To successfully scale VIA, substantial training and quality control efforts will be needed 
to maintain test performance. 
To date, HPV testing and VIA have generally been limited to clinical studies and demonstration 
projects in India.2 A notable exception is the Tamil Nadu Health Systems Project, which piloted a large-
scale government-led VIA program in 2007. By 2015, the program achieved 71% coverage of women 
aged 30 to 60 years.27 While the program demonstrated the feasibility and acceptability of a cervical 
cancer screening program within the public health sector in one state, it also identified implementation 
challenges. Many of the women referred to treatment did not receive it, as women were referred to 
colposcopy at higher level facilities rather than receiving immediate treatment following a positive 
screening test.28 Furthermore, the project was supported by the World Bank (US$19 million for the non-
communicable disease program targeting cardiovascular disease, breast cancer, and cervical cancer), 
highlighting the importance of multilateral institutions and the international donor community in 
strengthening health systems and building capacity to expand the reach of screening programs. 
There are several limitations to our analysis. Our modelled screening algorithms assumed that 
currently available technologies could facilitate screening and treatment of precancer in one or two 
visits with VIA or HPV testing, respectively. While this may be the case at higher level facilities with 
cryotherapy available on-site, the equipment and compressed gas needed for cryotherapy are not 
available at most primary health facilities in India. Thus, women may be required to bear the time and 
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travel costs to attend a referral facility, reducing the likelihood of receiving treatment. However, the 
coverage rates we assumed are lower, covering a much narrower age range (30 to 34 years) than the 
71% coverage achieved in the Tamil Nadu Health Systems Project for women aged 30 to 60 years, and 
might resemble program coverage rates if initial efforts focused on delivery of screen-and-treat 
algorithms in referral centers and/or mobile clinics to ensure on-site availability of ablative treatment. 
While it is possible that delayed implementation could yield higher population coverage than immediate 
implementation, this would require very rapid deployment of resources and capacity building, as well as 
social mobilization and outreach. In India, where 67% of the population lives in rural areas,29 our 
assumptions of high compliance with treatment (100% with VIA; 80% with two-visit HPV testing) among 
screen-positive women eligible for cryotherapy are more likely to be achievable when the number of 
required visits for a screening episode are low and treatment is proximal. Furthermore, we did not 
consider the impact of catch-up HPV vaccination in older women over age 30 years, for which the cost-
effectiveness has not been demonstrated in low-resource settings. 
The accuracy of microsimulation model projections depends upon the validity of our calibration 
approach. While we calibrated the model to fit epidemiologic data from IndiaͶ using the expected 
value outcomes from 50 good-fitting sets of natural history inputs to reflect uncertaintyͶ the high-risk 
HPV prevalence from a large demonstration project in Hyderabad6 and the Nagpur cancer registry18 do 
not fully capture the geographic variation in disease burden across India. Furthermore, our data on age-
specific prevalence of high-risk HPV was restricted to women aged 30 to 49 years. However, exercises to 
validate model projections suggest internal consistency between our calibrated model, test 
performance characteristics for VIA and HPV testing drawn from a demonstration project in a public 
sector clinic in Hyderabad,6 and two large randomized trials of screening impact in India that were not 
used to derive model inputs (Appendix).24, 25 The calibrated and validated microsimulation model 
allowed us to estimate age-specific cervical cancer incidence and mortality reductions resulting from 
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nuanced screening and management algorithms, given uncertainty in the natural history parameters 
and epidemiologic data. 
Our modeling approach assumed that the burden of HPV and cervical cancer were consistent 
over the lifetime of women aged 30 to 34 years between 2017 and 2026. A recent modeling analysis 
used age-period-cohort models to project the future number of new cervical cancer cases in six Baltic, 
central, and eastern European countries through 2040.30 Based on recorded trends in the most recent 
generations, these projections assumed cervical cancer incidence continued to increase across the study 
period. It is unclear whether cervical cancer burden is also increasing in India, although HPV 
transmission models (which integrate sexual behavior data) might inform estimates of future cancer risk 
among young women at or approaching screening age. We note that if GLOBOCAN 2012 underestimates 
the future cancer risk of women who will become eligible for screening over the intervention period we 
consider, we may underestimate the number of cases averted due to organized screening. 
The present analysis does not address the cost-effectiveness or affordability of implementing a 
screening program, although both the value and budget impact need to be favorable in order for a 
program to be sustainable. Elsewhere, we have estimated the cost-effectiveness of various screening 
strategies in India, and found that a two-visit approach with HPV DNA ƚĞƐƚŝŶŐƚŚƌĞĞƚŝŵĞƐŝŶĂǁŽŵĂŶ͛Ɛ
lifetime would be very cost-effective, with an incremental cost-ĞĨĨĞĐƚŝǀĞŶĞƐƐƌĂƚŝŽďĞůŽǁ/ŶĚŝĂ͛ƐƉĞƌ
capita GDP.13 We have found that the value of new technologies such as point-of-care HPV testing in 
India is potentially high if linkage to treatment can be assured.31 Furthermore, we have also estimated 
the financial cost of screening women aged 35 years in India with HPV testing or VIA once in a lifetime to 
be US$830 million over 10 years (or approximately US$83 million per year); however, this scenario 
represents an upper bound, as it assumed the program would reach full coverage within five years.32 To 
place this figure in context, US$1.08 billion of development assistance for health was disbursed to India 
in 2013.33 Decision makers will need to weigh the value and financial cost of implementing organized 
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cervical cancer screening in relation to other disease priority areas. Development assistance will be 
required for screening implementation. We present these findingsͶ which suggest that immediate 
implementation of HPV testing has the potential to save the lives of hundreds of thousands of women in 
India who are beyond the target age of HPV vaccinationͶ to catalyze the policy dialogue. This analysis 
quantifies the human cost of waiting to act, despite the availability of screening technologies with 
demonstrated effectiveness and cost-effectiveness; this toll only increases over time. 
Implementation of organized screening programs is difficult work, requiring political will and 
coordination across levels of the health care system. A one-size-fits-all approach is unlikely to work 
across all states or districts within a state. Without injection of funds from the international donor 
community to strengthen health systems and support cancer prevention efforts, as well as 
governmental budgetary allocations and commitment to sustainability, the costs of cervical cancer 
screening will fall predominantly on women and their families; achieving high coverage and 
management of screen-positive women will remain a barrier to successful programs. Despite these 
challenges, our study provides quantitative evidence that the failure to begin prompt implementation of 
cervical cancer screening in India with currently available technologies will result in substantial 
morbidity and mortality among women who are critical to social and economic stability.  
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Figure legend. 
Figure 1. Cumulative number of expected averted cervical cancer A) cases and B) deaths are presented 
for the following screening strategies: 1) immediate two-visit human papillomavirus (HPV) DNA testing 
followed by a switch to one-visit HPV DNA testing after five years (dark blue line); 2) immediate visual 
inspection with acetic acid (VIA) followed by a switch to one-visit HPV DNA testing after five years 
(orange line); 3) immediate two-visit HPV DNA testing (red line); 4) immediate VIA (yellow line); 5) 
delayed one-visit HPV DNA testing (turquoise line); 6) delayed two-visit HPV DNA testing (purple line); 
and 7) delayed VIA (green line). Immediate implementation strategies for once in a lifetime screening 
assume 10% coverage each year of women aged 30 to 34 years in India between 2017 and 2021, and 
20% coverage each year of women aged 30 to 34 years between 2022 and 2026. Delayed 
implementation strategies assume no coverage of women aged 30 to 34 years between 2017 and 2021, 
and 10% coverage each year of women aged 30 to 34 years between 2022 and 2026. The difference 
between the two-visit and one-visit HPV DNA testing strategies is that, in the two-visit strategy, 20% of 
women screened do not show up to receive HPV results and, if HPV-positive, treatment. In the one-visit 
strategy, all women who screen positive and are eligible are assumed to receive treatment with 
cryotherapy. 
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Table 1. Values and data sources for model variables.
a 
Variable Value Data source 
   
Age of target population 30 to 34 years Assumption 
Population coverage of screening program   
     Immediate implementation (2017) 10% (2017-2021), 20% 
(2022-2026) 
Assumption 
     Delayed implementation (2022) 10% (2022-2026) Assumption 
   
Individual-based Monte Carlo simulation model 
Loss to follow-up per visitb 20% Assumption 
Test sensitivity/specificity for CIN2+ 
     VIA 
     HPV DNA test (self-collection)c 
 
0·55/0·92 
0·76/0·95 
 
Jeronimo et al. 20146 
Eligibility for cryotherapyd 
     No lesion or CIN1 
     CIN2 
     CIN3 
     Cancer 
 
100% 
85% 
75% 
10% 
 
Campos et al. 201512 
 
Effectiveness of cryotherapy to treat 
CIN2/3 
92%  Sauvaget et al. 201313 
Chirenje et al. 200114 
Test sensitivity/specificity for CIN1+, 
colposcopye 
0·50/0·96 Jeronimo et al. 20146 
Effectiveness of cryotherapy/LEEP 
following colposcopy to treat CIN2/3 
96% Chirenje et al. 200114 
   
CERVIVAC population model   
Population and demographic dataf By age and year United Nations World 
Population Prospects, 2012 
Revision 15 
Cervical cancer incidence By age, in 5-year groupsg Globocan 20121 
Cervical cancer mortality By age, in 5-year groupsg Globocan 20121 
Reduction in cervical cancer incidence 
attributable to screening 
By age, in 5-year groups Individual-based Monte Carlo 
microsimulation model11 
calibrated to 1) age-specific 
prevalence of high-risk HPV in 
Hyderabad6 and 2) the  Nagpur 
cervical cancer registry (1998-
2002)16 
Reduction in cervical cancer mortality 
attributable to screening 
By age, in 5-year groups Individual-based Monte Carlo 
microsimulation model11 
calibrated to 1) age-specific 
prevalence of high-risk HPV in 
Hyderabad6 and 2) the  Nagpur 
cervical cancer registry (1998-
2002)16 
This article is protected by copyright. All rights reserved
A
cc
ep
te
d
 A
rt
ic
le
  
a CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; LEEP: loop electrosurgical excision 
procedure; VIA: visual inspection with acetic acid. 
b Loss to follow-up was defined as the proportion of women who do not return for each subsequent 
clinical encounter, relative to the previous visit. In the two-visit HPV DNA test strategy, loss to follow-up 
applied to the results/cryotherapy visit. In both the one-visit VIA, two-visit HPV DNA test, and one-visit 
HPV DNA test strategies, loss to follow-up applied to both the diagnostic confirmation and treatment 
visits for women who were not eligible for cryotherapy immediately following a positive screening test. 
c HPV DNA test performance characteristics (for self-collection of vaginal samples) were based on a 
demonstration project of the careHPV test in Hyderabad. We assumed the same test performance 
characteristics for 1- and two-visit HPV testing strategies. 
d Eligibility for cryotherapy immediately following a positive screening test was based upon a womĂŶ͛Ɛ
true health state in the model. 
e Test performance characteristics of colposcopy in the PATH START-UP demonstration project were 
derived from the worst diagnosis of the local pathologist relative to the worst diagnosis by a quality 
control pathologist (gold standard); we applied the treatment threshold of CIN1+, although this was not 
the treatment threshold in the START-UP project. To derive test performance of colposcopy, we 
excluded histological classifications that were inadequate or with a histological classification other than 
negative, CIN1, CIN2, CIN3, or cancer. Because CIN1 is not a true underlying health state in the 
microsimulation model, performance of colposcopy in the model is based on the underlying health 
states of no lesion, HPV infection, CIN2, or CIN3. For a treatment threshold of CIN1, we weighted 
sensitivity of colposcopy for women with HPV based on the prevalence of CIN1 among women with HPV 
infections in the START-UP studies. 
f Data from the United Nations World Population Prospects15 project female population sizes for single 
ages and single years from 1950 until 2100.  
g Globocan 201216 data was provided by the Institut Catala Ě͛KŶĐŽůŽŐŝĂĨŽƌĂƉƌĞǀŝŽƵƐůǇƉƵďůŝƐŚĞĚ
analysis17 in 5-year age groups from ages 30 to 49 years. Globocan data is collapsed into one age group 
for cervical cancer incidence and mortality rates over 75 years; in the CERVIVAC model, we linearly 
interpolated the rates in the oldest age groups, assuming that the Globocan data for 75 years and over 
applied to women aged 85 to 89 years and then decreased at a linear rate. 
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Table 2. Screening strategies and scale-up scenarios.
a 
Strategy Coverage level (% of women aged 30-34 years) and screening test by year 
 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 
Immediate implementation of currently available tests with moderate scale-up 
Immediate VIA 10 
1-v VIA 
10 
1-v VIA 
10 
1-v VIA 
10 
1-v VIA 
10 
1-v VIA 
20 
1-v VIA 
20 
1-v VIA 
20 
1-v VIA 
20 
1-v VIA 
20 
1-v VIA 
Immediate 2-
visit HPV 
10 
2-v HPV 
10 
2-v HPV 
10 
2-v HPV 
10 
2-v HPV 
10 
2-v HPV 
20 
2-v HPV 
20 
2-v HPV 
20 
2-v HPV 
20 
2-v HPV 
20 
2-v HPV 
Number of 
women 
screened 
5,185,700 5,252,500 5,309,800 5,359,100 5,399,000 10,862,300 10,916,700 10,969,200 11,025,800 11,096,500 
Immediate implementation of currently available tests followed by a switch to point-of-care HPV testing 
Immediate VIA, 
switch to 1-visit 
HPV 
10 
1-v VIA 
10 
1-v VIA 
10 
1-v VIA 
10 
1-v VIA 
10 
1-v VIA 
20 
1-v HPV 
20 
1-v HPV 
20 
1-v HPV 
20 
1-v HPV 
20 
1-v HPV 
Immediate 2-
visit HPV, switch 
to 1-visit HPV 
10 
2-v HPV 
10 
2-v HPV 
10 
2-v HPV 
10 
2-v HPV 
10 
2-v HPV 
20 
1-v HPV 
20 
1-v HPV 
20 
1-v HPV 
20 
1-v HPV 
20 
1-v HPV 
Number of 
women 
screened 
5,185,700 5,252,500 5,309,800 5,359,100 5,399,000 10,862,300 10,916,700 10,969,200 11,025,800 11,096,500 
Delayed implementation of currently available tests or point-of-care HPV testing 
Delayed VIA -- -- -- -- -- 10 
1-v VIA 
10 
1-v VIA 
10 
1-v VIA 
10 
1-v VIA 
10 
1-v VIA 
Delayed 2-visit 
HPV 
-- -- -- -- -- 10 
2-v HPV 
10 
2-v HPV 
10 
2-v HPV 
10 
2-v HPV 
10 
2-v HPV 
Delayed 1-visit 
HPV 
-- -- -- -- -- 10 
1-v HPV 
10 
1-v HPV 
10 
1-v HPV 
10 
1-v HPV 
10 
1-v HPV 
Number of 
women 
screened 
-- -- -- -- -- 5,431,200 5,458,300 5,484,600 5,512,900 5,548,200 
a 1-v: 1-visit strategy; 2-v: 2-visit strategy; HPV: HPV DNA testing; VIA: visual inspection with acetic acid. VIA testing is indicated by blue squares 
(light blue: 10% coverage; dark blue: 20% coverage). 2-visit HPV testing is indicated by the lavender shading (light lavender: 10% coverage; dark 
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lavender: 20% coverage). 1-visit (point-of-care) HPV testing is indicated by the yellow shading (light yellow: 10% coverage; dark yellow: 20% 
coverage). Each year, the relevant coverage level was applied to each birth cohort of women between age 30 and 34 years. Thus, depending on 
the year, cohort, and coverage level, effective coverage for a particular birth cohort could be zero (e.g., for 34 year old women in 2017 under 
delayed implementation scenarios), or nearly 100% (e.g., for 30 year old women in 2022 after immediate implementation with a switch to 1-visit 
HPV). 
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Table 3. Cervical cancer cases and deaths averted over the lifetimes of women aged 30 to 34 years during the intervention period 2017-2026 
in India, by cervical cancer screening implementation strategy.
a 
Strategy Number of 
women 
screened 
Cumulative 
cases averted 
Cumulative 
deaths averted 
Incremental 
number of 
cases averted 
relative to 
most effective 
strategy  
Incremental 
number of 
deaths averted 
relative to 
most effective 
strategy 
Immediate implementation (2017) followed by a switch to point-of-care HPV testing (2022) 
Immediate 
two-visit HPV, 
switch to one-
visit HPV 
81,377,000 574,100 382,500 -- -- 
Immediate 
VIA, switch to 
one-visit HPV 
81,377,000 521,900 346,600 -52,200 -35,900 
Immediate implementation of currently available tests (2017) with moderate scale-up (2022) 
Immediate 
two-visit HPV 
81,377,000 480,600 328,000 -93,500 -54,500 
Immediate VIA 81,377,000 330,800 217,900 -243,300 -164,600 
Delayed implementation of currently available tests or point-of-care HPV testing (2022) 
Delayed one-
visit HPV 
27,435,000 209,300 139,100 -364,800 -243,400 
Delayed two-
visit HPV 
27,435,000 165,900 111,600 -408,200 -270,900 
Delayed VIA 27,435,000 111,200 73,800 -462,900 -308,700 
a Strategies are listed in order of effectiveness. The target population included cohorts of women aged 30 to 34 years during implementation 
between 2017 and 2026. Cumulative cases and deaths extend over the lifetime of these cohorts, through 2095. Strategies considered for 
immediate implementation followed by a switch to point-of-care HPV testing included 1) Immediate two-visit HPV, switch to one-visit HPV: two-
visit HPV DNA testing with 10% coverage (implemented 2017-2021) scaling up to 20% coverage with one-visit HPV testing (implemented 2022-
2026); and 2) Immediate VIA, switch to one-visit HPV: one-visit VIA with 10% coverage (implemented 2017-2021) scaling up to 20% coverage 
with one-visit HPV testing (implemented 2022-2026). Strategies considered for immediate implementation included 1) Immediate two-visit HPV: 
two-visit HPV DNA testing with 10% coverage (implemented 2017-2021) scaling up to 20% coverage (implemented 2022-2026); and 2) 
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Immediate VIA: one-visit VIA with 10% coverage (implemented 2017-2021) scaling up to 20% coverage (implemented 2022-2026). Strategies 
considered for delayed implementation included: 1) Delayed one-visit HPV: one-visit HPV DNA testing with 10% coverage (implemented 2022-
2026); 2) Delayed two-visit HPV: two-visit HPV testing with 10% coverage (implemented 2022-2026); and 3) Delayed VIA: one-visit VIA with 10% 
coverage (implemented 2022-2026).  
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Novelty & Impact Statement: 
Nearly one-quarter of cervical cancer cases worldwide occur in India. Nonetheless, while the disease 
can be prevented in part through screening for precancerous lesions, very few Indian women receive 
Pap tests. Here, the authors estimated cervical cancer burden in India assuming different screening 
program implementation scenarios, including immediate implementation with both two-visit and one-
visit human papillomavirus (HPV) testing and delayed implementation with a one-visit HPV test. 
Models showed that immediate implementation of HPV testing averted more than double the number 
of cases and deaths from cervical cancer among 30- to 34-year-old women compared with delayed 
implementation with one-visit HPV testing.  
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